Adolescent exposure to benzophenone ultraviolet filters: cross-sectional associations with obesity, cardiometabolic biomarkers, and asthma/allergy in six European biomonitoring studies
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
40409449
DOI
10.1016/j.envres.2025.121912
PII: S0013-9351(25)01163-6
Knihovny.cz E-zdroje
- Klíčová slova
- Allergy, Benzophenone, Endocrine disruption, HBM4EU, Obesity, PARC, UV filter,
- MeSH
- alergie * epidemiologie MeSH
- benzofenony * toxicita moč škodlivé účinky MeSH
- biologické markery krev MeSH
- biologický monitoring MeSH
- bronchiální astma * epidemiologie chemicky indukované MeSH
- lidé MeSH
- mladiství MeSH
- obezita * epidemiologie chemicky indukované MeSH
- přípravky chránící proti slunci * škodlivé účinky MeSH
- průřezové studie MeSH
- vystavení vlivu životního prostředí * MeSH
- Check Tag
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
- Názvy látek
- benzofenony * MeSH
- biologické markery MeSH
- přípravky chránící proti slunci * MeSH
BACKGROUND: Exposure to benzophenone-1 (BP-1) and benzophenone-3 (BP-3), widely used as UV filters in personal care products, has been associated with adverse health effects. However, epidemiological evidence is limited and inconclusive, particularly in vulnerable populations such as teenagers. OBJECTIVE: To examine the relation between BP-1 and BP-3 concentrations and obesity, cardiometabolic biomarkers, and asthma/allergy outcomes in European teenagers, including possible sex-specific associations. METHODS: A multi-country cross-sectional study was conducted using pooled data from six aligned studies from the Human Biomonitoring for Europe Initiative (HBM4EU). Sociodemographic data, cardiometabolic biomarkers, and asthma/allergy outcomes were collected through questionnaires. Anthropometric data and BMI z-scores were calculated (n = 1339). Plasma/serum cardiometabolic biomarkers and asthma/allergy outcomes were available for a subsample (n = 173-594). Urinary BP-1 and BP-3 concentrations were adjusted for creatinine dilution using the traditional standardization (trad.) and the covariate-adjusted creatinine standardization (CAS) method. Generalized additive models, linear, logistic, and multinomial mixed models were applied, and sex-interaction terms were tested. RESULTS: Each natural log-unit increase in urinary BP-3 (CAS) concentrations was associated with higher odds of obesity in the whole population (OR: 1.20; 95%CI: 1.04-1.38). Sex-specific associations were also found with BP-1 (CAS) and BP-3 (CAS) concentrations, which were associated with higher odds of obesity in male teenagers (OR: 1.25; 95% CI: 1.01-1.55; OR: 1.34; 95%CI: 1.09-1.65, respectively). Linear mixed models showed consistent findings toward higher BMI z-scores. A negative association was found between BP-1 (CAS) concentration and serum adiponectin levels in females (% change per loge-unit increase: -3.73, 95%CI: -7.32, -0.10). BP-3 (CAS) concentrations were also associated with higher odds of non-food allergies in males (OR: 1.27; 95%CI: 1.00-1.63). Traditional creatinine adjustment showed similar or slightly attenuated estimates compared to the CAS method. CONCLUSIONS: BP-1 and BP-3 exposure was cross-sectionally associated with higher odds of obesity in European male teenagers, highlighting the need to update regulations and keep exposure levels as low as practically achievable. Longitudinal studies are needed to confirm these findings.
Department of Biomedical Sciences University of Antwerp Belgium
Department of Risk Benefit Assessment Swedish Food Agency Uppsala Sweden
German Environment Agency Berlin Germany
Instituto de Investigación Biosanitaria 2400 Mol Belgium
Instituto de Investigación Biosanitaria Spain
National Centre for Environmental Health Instituto de Salud Carlos 3 Majadahonda Madrid Spain
RECETOX Faculty of Science Masaryk University Brno Czech Republic
Toxicology Unit Research Institute of Biomedical and Health Sciences Spain
Unidad de Gestión Clínica de Laboratorios Hospital Universitario Clínico San Cecilio Granada Spain
University of Granada Biomedical Research Center Granada Spain
University of Granada Biomedical Research Center Spain
VITO Health Flemish Institute for Technological Research 2400 Mol Belgium
Citace poskytuje Crossref.org